Here at PDS, we take pride in highlighting some of our incredible exhibitors. We know these companies have the potential to revolutionize pharmacies just like yours through their products and services. We’re excited to introduce RxSafe. Read on for their blog post about pouch vs. blister in a COVID world.

This year has been full of changes and challenges for both patients and pharmacists. Coronavirus has increasingly led to many patients preferring “no-contact” or “touchless” services.  

Independent pharmacists can reduce the risk of COVID-19 transmission by limiting contact between staff and patients. Listen to Kyle Lomax and Traci Bayer, RxSafe customers, explain how they are meeting this new “contactless” demand. 

Will “Touchless” be the Norm?  

 When the pandemic first started, many people thought it would only last a few weeks. Since then, the rapid and sustained spread of the virus has increased patients’ desire for limited contact, especially with healthcare professionals. 

It is clear that this pandemic will have a lasting impact on the way patients interact with pharmacists. Patients are likely to use pharmacies that offer pouch packaging and “no-contact” delivery services.  

“Our delivery has almost quadrupled,” says Lomax. “I think that our commitment to this wide radius of delivery has really made us stand out in our role, especially in our rural communities.” 

Even after the widespread distribution of the COVID vaccine — which will take the better part of a year — patients may be more likely to limit their contact in order to avoid any type of virus or illness. 

Why is Pouch Packaging Safer? 

Traditional vial filling involves many touch points that increase the risk of transmission. Even after the prescription leaves the pharmacy, there are many more touch points that occur with consumption. William Holmes, CEO of RxSafe, details how quickly the number of touchpoints can grow with traditional vials. 

“Let’s presume now a family member might be assisting someone with opening and closing their vials, that’s 30 times a month that vial gets opened and closed and sometimes pills get poured out into a hand and then the bulk poured back,” explains Holmes. “With each touch, you’re increasing the risk of disease transmission.”  

On average, there are 317,000 touch points per 1,000 patients using the manual card fill system. Using an automated pill packager reduces the touchpoints to approximately 1,140 touch points.  

Pouch packaging automation, such as the RapidPakRx, can drastically reduce touch points. When consuming their medications, patients just have to tear open one pouch. Also, pouch packaging allows for a 31-day script to be filled, decreasing contact between patients and pharmacy staff.  

“Even during COVID, we’ve had very few people go without their medications,” says Bayer, “because their prescriptions are ready almost a week before they’re due.” 

Need additional information?

Learn more about how you can create efficient operations in the midst of COVID with the PDS COVID Optimization Program.  You can also get a sneak peek of the latest PDS member town hall to hear more about how independent pharmacies are adapting their operations to best serve their patients through COVID.

About

Here at PDS, we take pride in highlighting some of our incredible media partners. We know these companies have the potential to revolutionize pharmacies just like yours through their products and services. We’re excited to work with Pharmacy Times. Read on for their sponsored blog post about the importance of immunization programs, written by PDS member, Travis Wolff, PharmD and Emma Leffler, PharmD. Travis is the manager and co-owner of Med-World Pharmacy in Sapulpa, Oklahom and Emma is a PGY1 community pharmacy resident.

There are many areas of patient care where pharmacists can have a direct impact, yet a number of them do not have the confidence or understand the potential magnitude of that impact.  

Moving the Independent Pharmacy Forward with Immunizations

If pharmacists want to continue to move the profession forward, seeking provider opportunities, they must gain that confidence and help stakeholders understand the important roles they play. These include conducting diabetes or point-of-care testing, but it is immunizations that provide the clearest snapshot.  

Let’s go back to the years when pharmacists first saw immunization-friendly legislation being enacted from state to state. The National Association of Chain Drug Stores compared influenza vaccine rates from 2003 to 2013 to cover this period of pro-pharmacist legislation.

During that time:

• 5.1 million vaccinations could be attributed to the new legislation.
• The American Pharmacists Association (APhA) Foundation conducted a pilot study that looked at immunizations across 8 community pharmacies in Washington State.
• The study results showed that vaccine administration rates had increased by 41.4% over 6 months.
• In addition, for every influenza vaccine walk-in, 1.45 other vaccinations were identified as being due. Of those unmet patient immunization needs, 95% were administered by the pharmacist at the point of care.

Understanding the impact pharmacists have had after receiving immunization privileges greatly boosts the case that they should be given additional responsibilities. After we shared these two studies with our federal and local representatives, they asked us about the local community we served. This led us to dive into our own initiatives.  

Immunization Facts

We will start by laying out some important facts. Immunization is one of the most cost-effective means of preventing disease. Individuals can defend themselves against several diseases by staying up-to-date on all recommended immunizations. Additionally, as more individuals become protected from particular diseases, communities gain a collective immunity that aids in reducing complications, deaths, and hospitalizations. Community pharmacists can reach out to and educate patients in their communities, and administer these preventive immunizations to them.  

Some challenges that providers face are:

• Consistent accessibility to the adult patient population
• Identifying patient vaccine eligibility
• Supplying and administering all recommended immunizations in the office

Patient challenges range from access to reliable information, knowing which immunizations are recommended based on age or comorbidities, and remembering when to receive follow-up doses. By creating pharmacist-led immunization programs, community pharmacies can improve patient outreach, immunization rates, and follow-up doses.  

From the most current data up to 2016, overall immunization rates for hepatitis A (23.7%), human papillomavirus (8.6%), influenza (70.4%), pneumococcal disease (66.9%), shingles (37.4%), and tetanus, diphtheria, and pertussis (26.6%) have increased slightly. Pharmacists have the optimal opportunity to increase these rates around the nation. Our pharmacy targeted 1 specific immunization in 2019, the shingles vaccine Shingrix.  

Seeing it in Action

In 2019, we promoted Shingrix immunizations on our Facebook page and flyers, and through individual discussions with the patients we identified as being eligible to receive them. The determination of eligibility stemmed from our Sync+ program, which analyzes patient profiles to determine chronic disease medication adherence, immunization eligibility, and preventive screening opportunities. Patients aged 50 years or older were identified as eligible for the Shingrix vaccination. Our Sync+ patients were sorted through, alphabetizing by last name. This allowed for a staggered informing of eligibility versus a bombardment of vaccinations on a single day or week. When the program identified a patient as being eligible, we communicated a message through a written note in the patient’s Sync+ basket, as well as a typed note in the patient’s electronic profile. Pharmacy team members could then counsel patients at pick-up time about benefits, eligibility, and what to expect.  

Because of the advertisements and 1-on-1 counseling, our pharmacy, Med-World, more than doubled its Shingrix vaccination rates in 7 months versus the rate in 2018. Of the 447 patients we have analyzed thus far through Sync+, 74% are eligible for Shingrix immunization, 26% of whom have received it. Numerous patients identified have yet to receive their 1-on-1 counseling, because of when their pharmacy system sync day falls during the month.  

Many patients had questions about whether Shingrix is still given if they have already received the Zostavax immunization, and whether it is inactive or live. Patients who previously received Zostavax are still eligible, and we encourage them to receive the new shingles immunization. Although 

Zostavax is a live immunization and carries increased contraindications and precautions, Shingrix is an inactive immunization, which means greater availability to more people. Additionally, Shingrix is 97% effective at preventing shingles in people aged 50 years or older, whereas Zostavax is only 50% to 64% effective at preventing shingles in that age group.

Once patients receive their first immunization, we document the date of their next follow-up dose on their comprehensive immunization spreadsheet and computerized profile note. Each month, a staff member calls patients within the 2- to 6-month period to inform them that it is time for the last dose of Shingrix. When patients have received both doses, the staff make the appropriate documentation. In 2019, our program completed 3.5 times as many follow-up doses versus 2018.  

Conclusion: Independent Pharmacies Impact Immunization Rates

Based on our findings, community pharmacist immunization programs can have an extensive impact on immunization rates, especially regarding follow-up dose rates. Barriers to patient immunization initiation included the ability to contact patients, patients receiving the immunization at a different facility, and cost. Additional research and time are needed to determine the longterm impact that pharmacist-led programs have on immunization rates and follow-up doses. We plan to expand our immunization program to include other immunizations, such as hepatitis B, Pneumovax 23, and Prevnar 13B.  

We hope that community pharmacists across the nation will gain confidence and better understand how to communicate their value to stakeholders.  

If we can have this kind of impact on immunizations, what would the impact be across other point-of-care health services if pharmacists were entrusted with them?  

Next Steps:

Join the PDS Innovate in a Day event on February 11 where we will be talking more about immunizations and other strategies you can implement in your pharmacy now to propel your business forward in 2021.

References